Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

The objective of this review is to assess the effects of Bruton tyrosine kinase (BTK) inhibitors in the treatment of adults with chronic lymphocytic leukemia (CLL), given alone or in combination with other agents, in comparison to existing anti-leukemic therapies such as cytotoxic chemotherapy, monoclonal antibodies, or other small-molecule inhibitors. We plan to assess efficacy, safety, and quality-of-life outcomes, in order to summarize the available evidence and better inform clinical practice and future research.

This is a protocol.